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Abstract Cardiac atrial natriuretic peptide (ANP) locally
counteracts cardiac hypertrophy via the guanylyl cyclase-A
(GC-A) receptor and cGMP production, but the down-
stream signalling pathways are unknown. Here, we exam-
ined the inﬂuence of ANP on b-adrenergic versus
Angiotensin II (Ang II)-dependent (Gs vs. Gaq mediated)
modulation of Ca
2?
i-handling in cardiomyocytes and of
hypertrophy in intact hearts. L-type Ca
2? currents and
Ca
2?
i transients in adult isolated murine ventricular myo-
cytes were studied by voltage-clamp recordings and ﬂuo-
rescence microscopy. ANP suppressed Ang II-stimulated
Ca
2? currents and transients, but had no effect on isopro-
terenol stimulation. Ang II suppression by ANP was
abolished in cardiomyocytes of mice deﬁcient in GC-A, in
cyclic GMP-dependent protein kinase I (PKG I) or in the
regulator of G protein signalling (RGS) 2, a target of PKG
I. Cardiac hypertrophy in response to exogenous Ang II
was signiﬁcantly exacerbated in mice with conditional,
cardiomyocyte-restricted GC-A deletion (CM GC-A KO).
This was concomitant to increased activation of the Ca
2?/
calmodulin-dependent prohypertrophic signal transducer
CaMKII. In contrast, b-adrenoreceptor-induced hypertro-
phy was not enhanced in CM GC-A KO mice. Lastly,
while the stimulatory effects of Ang II on Ca
2?-handling
were absent in myocytes of mice deﬁcient in TRPC3/
TRPC6, the effects of isoproterenol were unchanged. Our
data demonstrate a direct myocardial role for ANP/GC-A/
cGMP to antagonize the Ca
2?
i-dependent hypertrophic
growth response to Ang II, but not to b-adrenergic stimu-
lation. The selectivity of this interaction is determined by
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signalling. Furthermore, they strengthen published obser-
vations in neonatal cardiomyocytes showing that TRPC3/
TRPC6 channels are essential for Ang II, but not for
b-adrenergic Ca
2?
i-stimulation in adult myocytes.
Keywords ANP   Angiotensin II   cGMP-dependent
protein kinase   RGS2   Cardiac hypertrophy
Introduction
Cardiacatrialnatriureticpeptide(ANP)lowersarterialblood
pressureandintravascularvolumebyacombinationofdirect
and indirect effects that involve vasodilatation, increases in
endothelial permeability, stimulation of renal function, and
inhibition of the sympathetic as well as renin–angiotensin–
aldosterone (RAA) systems [25, 26]. These actions of ANP
are mediated by a membrane-bound guanylyl cyclase (GC)
receptor, GC-A, which mediates increases in intracellular
cyclicGMPlevelsinresponsetoANPbinding[25,26].Mice
with global disruption of the GC-A gene (GC-A-/- mice)
not only have increased systemic arterial blood pressure but
also display a marked cardiac hypertrophy which is dispro-
portionate to their increased blood pressure and partly
resistant to antihypertensive medication [23, 28]. Extending
thesestudies,ourownobservationsinmicewithconditional,
cardiomyocyte-restricted deletion of GC-A (CM GC-A KO
mice) demonstrated that ANP, via GC-A/cGMP signalling,
exerts important local, auto/paracrine functions to moderate
pathological cardiomyocyte growth [18]. The intracellular
signalling pathways mediating the local antihypertrophic
effects of ANP/GC-A are unknown. Because patients with
essential hypertension and/or cardiac hypertrophy/insufﬁ-
ciency exhibit diminished systemic and cardiac responsive-
ness to ANP [25, 26], clariﬁcation of this issue is important
from a physiological and also pathophysiological
perspective.
On the opposite, the RAA system enhances arterial
blood pressure and volume. Angiotensin II (Ang II) is a
potent vasoconstrictor, it increases sympathetic tone and
exerts indirect antidiuretic and antinatriuretic actions via
stimulation of aldosterone and antidiuretic hormone (ADH)
secretion [21]. Besides these systemic actions, locally
produced Ang II exerts direct trophic actions within the
heart, inducing cardiomyocyte hypertrophy, ﬁbroblast
proliferation and interstitial ﬁbrosis, thereby contributing to
pathologic cardiac remodelling [4, 32, 40]. Both the
hypertensive and cardiac hypertrophic as well as proﬁb-
rotic actions of Ang II are mediated through the Ang II type
1 (AT1) receptor [4, 37, 39].
Importantly, ANP counter regulates not only the sys-
temic but also the cardiac effects of the RAA system. It
inhibits renin release and Ang II-stimulated aldosterone
production [29, 31] and antagonizes the vasoconstrictor,
sympathotonic, and antinatriuretic actions of Ang II [22],
but also inhibits trophic effects of Ang II on cultured car-
diac myocytes and ﬁbroblasts [9]. Thus, the physiological
balance between the ANP/GC-A and Ang II/AT1 systems
is not only involved in the endocrine maintenance of
arterial blood pressure and intravascular volume homeo-
stasis, but also in the local, paracrine regulation of cardiac
growth.
Cardiac myocytes respond to increased mechanical
work-load or to neurohumoral stressors, such as Ang II by
altering the frequency and amplitude of their calcium
transients [1, 8, 16]. Encoded in these calcium responses
are signals that, at difference to b-adrenergic stimulation,
alter not only immediate contractility, but also initiate and
maintain a remodelling response that adjusts cellular mass,
ionic currents, kinetic properties of contractile proteins,
and metabolic capacity [16]. Persistence of these signals
modulates the calcium signalling events resulting in a
hypertrophic response and adverse remodelling. Recent
work indicates that hypertrophic agonists linked to Gaq-
protein coupled receptors such as Ang II activate calcium
entry through transient receptor potential canonical
(TRPC) channels [34] and that these channels, especially
TRPC1, C3 and C6, can trigger pathologic, hypertrophic
calcium signalling in the heart [34, 41]. In contrast, phys-
iological (e.g. exercise-induced) or b-adrenergic modula-
tion of myocyte calcium and growth apparently does not
involve TRPC channels. However, this hypothesis is
mostly based on the work with cultured neonatal rat
myocytes [34], which exhibit important structural, bio-
chemical and functional differences to adult cardiac
myocytes.
To gain new insights into the intracellular signalling
pathways mediating the local antihypertrophic effects
of ANP/GC-A, we compared the inﬂuence of ANP on
b-adrenergic versus Ang II-dependent (Gs vs. Gaq medi-
ated) modulation of Ca
2?
i handling in cardiomyocytes and
of cardiac hypertrophy in mice. The results demonstrate the
role and functional compartmentation of cGMP and cGMP-
dependent protein kinase type I (PKG I) stimulation by
ANP in the heart. They also emphasize that TRPC3/TRPC6
channels are essential for the increase of [Ca
2?]i in adult
myocytes by Ang II, but not by isoprenaline.
Materials and methods
Genetic mouse models
Mice with conditional, cardiomyocyte-restricted deletion
of the GC-A receptor (CM GC-A KO mice) and control
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123littermates (ﬂoxed GC-A mice, with normal GC-A
expression levels) were generated and genotyped as
described [18]. Transgenic mice with genetic deletion of
PKG I [49], regulator of G protein signalling (RGS)-2 [15]
or TRPC3/C6 channels and respective control mice were
obtained from collaborating laboratories. The PKG I
mutants were so-called SM-Ib rescue mice [49]. These
mice carry the SM-Ib transgene that restores expression of
the PKG Ib isozyme selectively in smooth muscle cells, but
not in other cell types of PKG I null mice (genotype PKG
I
L-/L-;SM-Ib
?/-). As controls, litter- and gender-matched
mice expressing endogenous PKG I and the SM-Ib trans-
gene were used (genotype PKG I
?/L-; SM-Ib
?/-). TRPC3/
TRPC6
-/- were generated by crossing the TRPC3
-/- [11]
and TRPC6
-/- [3] mouse lines. All investigations conform
with the guidelines for the care and use of laboratory ani-
mals (National Institutes of Health, Publication No 85–23,
revised 1996) and were approved by the local animal care
committee.
Measurement of cardiomyocyte Ca
2?
i transients
and single-cell contractility
Adult ventricular myocytes were isolated by liberase/
trypsin digestion [for Procedure see Protocol PP00000125
from The Alliance for Cellular Signalling (AfCS)]. Whole-
cell Ca
2?
i transients together with simultaneously recorded
cell length were measured in INDO-1 loaded, electrically
paced (0.5 Hz) cardiomyocytes as described before [20].
Excitation was at 365 nm, and the emitted ﬂuorescence
was recorded at 405 and 495 nm. The ratio of ﬂuorescence
at the two wavelengths was used as an index of the cyto-
solic Ca
2? concentration. Data were collected at 20 Hz,
and acquisition and processing were supported by Felix
software (Felix version 1.1, Photon Technologies, Seefeld,
Germany) [20]. After obtaining basal recordings for
10 min, myocytes were exposed to Ang II (10 nM) or
isoproterenol (ISO, 100 nM; both Sigma, Taufkirchen,
Germany) in the presence or absence of ANP (mouse ANP,
100 nM; Bachem, Heidelberg, Germany) (superfusion of
cardiomyocytes with ANP or vehicle during 10 min; then
superfusion with Ang II or ISO in the presence of ANP
during additional 10 min).
Electrophysiological recordings on ventricular
myocytes
Single cardiomyocytes were studied using the whole-cell
conﬁguration of the patch-clamp technique [24]. For
recordings, cells were plated in a small dish (2 cm Ø) on
the stage of an inverted microscope (Leica, Cologne,
Germany) directly before the start of the measurements.
For voltage-clamp recordings of L-type Ca
2? channel
activity the extracellular solution was composed of (mM):
NaCl 135.0, MgCl2 0.53, Na2HPO4 0.33, HEPES 5.0,
glucose 5.5, CaCl2 1.8, adjusted to pH 7.4 with NaOH. The
micropipette electrodes (resistances 2.0–3.5 MX) were
ﬁlled with (mM): CsCl 120.0, EGTA 10.0, MgCl2 1.0,
MgATP 4.0, HEPES 5.0, adjusted to pH 7.2 with CsOH.
Holding potential was -90 mV. Currents were elicited by
a ﬁrst voltage step to -50 mV for 70 ms to evoke NaV-
channel activity followed by a depolarization to 0 mV for
600 ms to activate L-type Ca
2? channel-mediated current.
For current-clamp recordings, bath solution was composed
of (mM): NaCl 143.0, Na2HPO4 0.25, KCl 5.4, CaCl2 1.8,
MgCl2 0.5, glucose 5.6, HEPES 5.0, adjusted to pH 7.35
with NaOH. Pipette solution for these recordings was
composed of (mM): KCl 125.0, CaCl2 1.0, MgCl2 1.0,
EGTA 11.0, HEPES 10.0, sucrose 10.0, adjusted to pH 7.2
with KOH. All experiments were done at room tempera-
ture. Recordings were performed with an EPC9 Patch-
Clamp ampliﬁer (HEKA, Lambrecht, Germany) and
analyzed with PulseFIT software (HEKA, Lambrecht,
Germany) [24].
Effect of ANP/PKG I on expression and subcellular
localization of RGS2 in HEK 293 cells
Human embryonic kidney (HEK)-293 cells stably
expressing GC-A were transiently cotransfected with
cDNAs coding for human regulator of G protein signalling
(RGS) 2 and PKG Ia using FuGENE reagent according to
manufacturer0s instructions (Roche, Mannheim, Germany).
After 2 days of transfection, the cells were treated with
ANP (10 nM) or vehicle for the indicated time. For sepa-
ration of the cytosolic, membrane, and nuclear proteins, a
cell fractionation kit was applied (nano-TOOLS Antiko ¨r-
pertechnik, Teningen, Germany). SDS-PAGE and immu-
noblotting were performed as previously described [12].
Antibodies were against GC-A [12], PKG I [48], RGS2
(ProteinTech Group, Chicago, USA) and GAPDH. The
blots were developed using the ECL detection system
(Amersham-Pharmacia, Freiburg, Germany) and the results
were quantitated by densitometry (ImageQuant) [12, 20].
Chronic treatment of mice with Ang II or ISO
Control and CM GC-A KO mice were infused subcutane-
ously with vehicle, Ang II (250 ng/kg BW/min, 2 weeks)
or ISO (40 mg/kg BW/day, 7 days [5]) via osmotic mini-
pumps (model 2002; Alzet, Colorado City, CO). Male and
female mice 4–6 weeks old were examined (n = 8–12
mice per group). Arterial blood pressure was measured in
conscious mice of the three treatment groups by tail cuff
(Softron, Tokyo, Japan) [18, 20]. Mice were then killed
under urethane anesthesia, the hearts were weighed and the
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123left ventricles were bisected and frozen in liquid nitrogen
(for protein extraction) and ﬁxed in 4% buffered formal-
dehyde (for histology).
Histology
For histological analysis, formaldehyde-ﬁxed left ventri-
cles were embedded in parafﬁn, and 5-lm sections were
stained with hematoxylin eosin or periodic acid Schiff
(PAS, to discriminate cardiomyocyte cell borders) [18, 20].
Photomicrographs of the sections were evaluated using the
computer-assisted image analysis system Cell-D (Olympus,
Hamburg Germany), with the investigator blinded to the
genotypes. The mean cross-sectional cardiomyocyte
diameters were calculated by measuring 100 cells with a
centrally located nucleus per specimen.
Western-blot analyses
Left ventricular proteins were solubilized in SDS—sample
buffer and separated by 10% PAGE. The primary anti-
bodies were against CaMKII (BD Transduction Laborato-
ries) and autophosphorylated (active) CaMKII (Santa
Cruz). GAPDH was used to control equal loading. The
blots were developed using the ECL detection system and
the results were quantitated by densitometry.
Statistics
The results are presented as mean ± SEM. Group data
were compared using one-way or two-way ANOVA (with
genotype and treatment as categories) followed by the
multiple comparison Bonferroni t test to assess differences
between groups. The signiﬁcance level was set at P\0.05.
Results
ANP inhibits the Ca
2? responses of adult mouse cardiac
myocytes to Ang II, but not to ISO
Single-cell ﬂuorescence imaging of Ca
2?
i transients in
Indo-1AM loaded ventricular myocytes showed that both
Ang II (10 nM) and ISO (100 nM) led to prompt and
marked increases in systolic Ca
2?
i levels and thereby in the
amplitude of Ca
2?
i transients (Fig. 1a, b). The responses
were accompanied by increased sarcomere shortening
(Fig. 1c, d). The exposure of isolated myocytes to 100 nM
ANP did not change the resting Ca
2?
i transient or basal
sarcomere shortening (Fig. 1a–d). However, ANP had very
different effects on the responses to ISO and Ang II. Cal-
cium and shortening responses to Ang II were totally
prevented by ANP (100 nM, 10-min pretreatment)
(Fig. 1a, c). In contrast, ANP did not affect calcium and
shortening responses to ISO (Fig. 1b, d).
This disparity was further revealed in electrophysio-
logical recordings of L-type Ca
2? currents. Currents
through L-type Ca
2? channels were measured using the
patch-clamp technique in the whole-cell conﬁguration. Ang
II (10 nM) and ISO (100 nM) both acutely ampliﬁed Ca
2?
current densities (Fig. 2a–d). ANP (100 nM) alone did not
affect L-type Ca
2? current densities (Fig. 2b, d). Pretreat-
ment with ANP fully inhibited Ang II-stimulation of
L-type Ca
2? channel activity (Fig. 2b) and had no effect on
ISO-stimulation of L-type Ca
2? channel activity (Fig. 2d).
Taken together, these experiments demonstrate that
ANP selectively inhibits the myocyte calcium responses to
Ang II, but not to b-adrenergic stimulation.
The inhibitory effects of ANP on myocyte
Ca
2? responses to Ang II are mediated by GC-A/
cGMP/PKG I-dependent modulation of RGS2
Next, we examined the receptor and post-receptor signal-
ling cascade which mediates inhibitory effects of ANP on
calcium responses to Ang II. First, to elucidate whether the
GC-A receptor is involved, we compared effects of ANP
on Ca
2?
i transients in isolated adult ventricular myocytes
from mice with cardiomyocyte-restricted GC-A-deletion
(CM GC-A KO) and respective control littermates. Myo-
cyte diastolic and systolic Ca
2?
i levels and amplitudes of
Ca
2? transients were not different between genotypes
(Fig. 3a). Superfusion of myocytes with Ang II (10 nM)
induced acute increases of free systolic Ca
2?
i levels in both
genotypes. ANP fully prevented the Ca
2?
i responses of
control myocytes to Ang II. In contrast, the Ca
2?
i
responses of GC-A-deﬁcient myocytes to Ang II were not
altered by ANP (Fig. 3a). We conclude that GC-A/cGMP
signalling mediates the counteraction of myocyte Ca
2?
responses to Ang II by ANP.
Several cGMP-modulated proteins are expressed in
myocytes, such as phosphodiesterases (PDE 2, 3 and 9) and
PKG I [47]. To investigate the possible contribution of
PKG I, we took advantage of a genetic smooth muscle
rescue mouse model that lacks expression of PKG I in
cardiomyocytes (mouse genotype: PKG I
L-/L-;SM-Ib
?/-;
PKG I
-/- myocytes) [49]. As shown in Fig. 3b, basal
Ca
2?
i transients and calcium responses to Ang II were in
PKG I
-/- like in respective control myocytes. However,
while in respective control myocytes the stimulatory
effects of Ang II were fully abolished in the presence of
ANP, in PKG I
-/- myocytes ANP pretreatment could not
prevent the calcium-stimulating effects of Ang II (Fig. 2b).
Corroborating these ﬁndings, the inhibitory effects of ANP
in control myocytes were completely prevented by the
selective PKG I inhibitor Rp-8-Br-PET-cGMP (10 lM,
586 Basic Res Cardiol (2010) 105:583–595
123pretreatment for 30 min before addition of ANP and Ang
II; Biolog, Hamburg, Germany), conﬁrming PKG I-medi-
ated effects (Fig. 3b).
Our observation that the ANP/GC-A/cGMP/PKG I
pathway inhibits the myocyte Ca
2? responses to Ang II but
not to ISO, seemed to indicate a selective modulation of
Gaq/11-coupled receptor signalling. The regulator of G
protein signalling (RGS)-2 is a selective and negative
regulator of Gq/11 proteins in the cardiovascular system
which is activated by PKG I [51]. To study whether RGS2
mediates effects of ANP, we compared myocytes from
RGS2-deﬁcient mice and controls [15]. Because 10 nM
Ang II often provoked arrhythmias in RGS 2
-/- myocytes
(not shown), instead we studied their responses to 1 nM
Ang II. As shown in Fig. 3c, the calcium responses of RGS
2-deﬁcient myocytes to 1 nM Ang II were greater as the
responses of respective wild-type myocytes (controls) to
10 nM Ang II. The calcium and shortening responses of
RGS2
-/- myocytes to ISO were unaltered (not shown).
Figure 3c also shows that the inhibitory effect of ANP on
the calcium responses to Ang II was totally abolished in
RGS2
-/- myocytes.
Collectively, our ﬁndings are compatible with the notion
that PKG I is the downstream target activated by the ANP/
GC-A/cGMP-signalling pathway in cardiac myocytes.
cGMP/PKG I-mediated modulation of RGS2 and sub-
sequent inhibition of AT1/Gaq signalling appear to mediate
the speciﬁc counter regulation of the calcium responses of
myocytes to Ang II by ANP.
Activation of the ANP/GC-A/PKG I pathway
in HEK293 enhances the expression and membrane
localization of RGS2
To study whether the ANP/GC-A/PKG I system can
modulate the expression or subcellular localization of
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c, d) in ﬁeld-stimulated
myocytes at baseline and during
superfusion with either Ang II
(10 nM) or ISO (100 nM) in the
presence or absence of ANP
(100 nM, 10 min pretreatment).
Top original tracings of Ca
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i
transients. Bottom
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123RGS2, we compared the relative amounts of RGS2 protein
in cytoplasmic and membrane fractions of transfected
HEK293 cells before and after PKG I activation by ANP.
As shown in Fig. 4, ANP (10 nM, incubation for 30, 60
and 120 min) caused a time-dependent increase in the total
expression of RGS2 as well as in the amount of RGS2
associated with the plasma membrane. After 2 h, the
expression of RGS2 increased by 5.9-fold (in the cytosol)
and 8.6-fold (at the plasma membrane) in ANP-treated
when compared with untreated cells.
Mice with cardiomyocyte-restricted deletion of GC-A
show exacerbated cardiac hypertrophy in response
to Ang II, but not to ISO
To elucidate whether these selective interactions between
ANP and Ang II, but not ISO signalling play a role in vivo,
in intact hearts, we compared the cardiac hypertrophic
responses of CM GC-A KO and respective control litter-
mates [18] to exogenous Ang II or ISO administration. It
should be emphasized that the cardiac effects are abolished
whereas all systemic functions of ANP/GC-A are preserved
in CM GC-A KO mice [18]. Ang II (250 ng/kg BW/min,
14 days) or ISO (40 mg/kg BW/day, 7 days [5]) were
administered s.c. via osmotic minipumps. Unexpectedly,
contrasting with many published studies [19 and others], in
our hands this low, so-called ‘‘suppressor’’ Ang II dose
provoked signiﬁcant increases in arterial blood pressure
(increases in systolic blood pressure levels by *30 mm
Hg; see Fig. 5a). Hypertensive reactions were similar in
mice from both genotypes. In contrast, ISO essentially had
no effect on blood pressure (Fig. 5a). In both genotypes,
chronic administration of Ang II or of ISO led to signiﬁcant
cardiac hypertrophy, as demonstrated by the increases in
the left ventricular (LV) weight - to - body weight (BW)
ratios (Fig. 5b) and the enlargement of LV myocyte
diameters (Fig. 5c). Notably, these effects of Ang II on
cardiac remodeling were more pronounced in CM GC-A
KO mice than in controls (Fig. 5b, c), despite the similar
hypertensive reactions. In contrast, the hypertrophic effects
of ISO were not different between genotypes (Fig. 5b, c).
We conclude from these in vivo data that a chronic inhi-
bition of the local, cardiac effects of ANP exacerbates the
hypertrophic actions of Ang II, but not of b-adrenergic
stimulation.
Enhanced Ang II-induced cardiac hypertrophy in CM
GC-A KO mice is accompanied by greater activation
of the Ca
2?/calmodulin-dependent kinase II pathway
Because increases in cytoplasmic Ca
2? can induce car-
diomyocyte hypertrophy through Ca
2?/calmodulin-medi-
ated activation of CaMKII signalling [30], we assessed the
activity of this pathway. The cardiac left ventricular
expression of total CaMKII was not different between
genotypes and/or treatment groups (Fig. 6 top). However,
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123the levels of autophosphorylated (active) CaMKII were
increased in CM GC-A KO mice already under basal
conditions (vehicle treatment; Fig. 6a, b). In control mice
chronic Ang II or ISO treatment signiﬁcantly increased
cardiac CaMKII autophosphorylation. The effect of Ang II
was markedly enhanced in CM GC-A KO mice (Fig. 6a).
In contrast, ISO treatment did not further increase pCaM-
KII levels in hearts of CM GC-A KO mice (Fig. 6b).
TRPC3/C6 channels are involved in the calcium
responses of adult cardiac myocytes to Ang II,
but not to ISO
Although TRPC3 and TRPC6 channels have been impli-
cated as essential elements mediating calcium and growth
responses of neonatal cardiomyocytes to Ang II [34], their
role in adult myocytes remained unexplored. To elucidate
whether the Ca
2?
i responses of adult cardiomyocytes to
Ang II are mediated by TRPC3/C6 activation, ﬁrst, we
studied the calcium responses to Ang II in adult cardio-
myocytes from double KO mice with genetic deletion of
both TRPC3 and TRPC6 (TRPC3
-/-/C6
-/-)[ 3, 11]. As
shown in Fig. 7a–d, the baseline Ca
2?
i transients of control
and TRPC3
-/-/C6
-/- cardiomyocytes were similar. Basal
Ca
2?-current densities were also similar and amounted to
-6.06 ± 0.61 pA/pF in control and to -6.21 ± 0.59 pA/
pF in TRPC3
-/-/C6
-/- cardiomyocytes (11 cells from 2
animals per genotype). The stimulatory effects of Ang II
(10 nM) on Ca
2?
i transients (ﬂuorometric measurements;
Fig. 7a) and L-type Ca
2? currents (Fig. 8a, b) were com-
pletely absent in TRPC3
-/-/C6
-/- cardiomyocytes. In
contrast, the effects of ISO (100 nM) on Ca
2?
i transients
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123(Fig. 7b) and L-type Ca
2? currents (Fig. 8c, d) were not
different between genotypes. Corroborating these obser-
vations, in control myocytes the inhibition of TRPC
channel activity with the 3,5-bis(triﬂuoromethyl)pyrazole
derivative, BTP2 (2 lM; Calbiochem [13]), fully abolished
the stimulatory effects of Ang II on Ca
2?
i transients
(Fig. 7c) and did not alter the effects of ISO (Fig. 7d).
Discussion
Major ﬁndings
The present studies in vivo and in isolated myocytes show
essentially that the ANP/GC-A/cGMP pathway counter
regulates cardiac Ang II, but not b-adrenergic stimulation of
calcium handling, of the calcium-dependent prohypertrophic
CaMKII pathway and of cardiac hypertrophy. The mecha-
nism behind this differential regulation of the Ang II versus
ISO responses by ANP involves PKG I and the regulator of
G protein signalling (RGS) 2, a major target of PKG I,
because the inhibitory effects of ANP on the Ca
2?
i
responses to Ang II were abolished in PKG I- or RGS2-
deﬁcient myocytes. Supporting these ﬁndings, in transfected
HEK293 cells ANP, via GC-A/PKG I, markedly induced the
expression of RGS2 and its translocation to the plasma
membrane. We conclude that ANP, via GC-A/cGMP/PKG I
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123signalling and activation of RGS2, speciﬁcally counter
regulates the hypertrophic effects of agonists linked to Gaq-
protein coupled receptors, such as Ang II. In contrast, ANP
does not affect b-adrenergic modulation of cardiac calcium
handling and myocyte growth. Lastly, our study extents and
strengthens previously published observations in neonatal
cardiomyocytes [34] demonstrating for the ﬁrst time that
transient receptor potential canonical TRPC3/C6 channels
are indispensable for the calcium responses of adult myo-
cytes to Ang II and are not involved in calcium responses to
b-adrenergic stimulation.
Differential regulation of cardiac Ang II,
but not b-adrenergic responses by ANP
Our results are in accordance with previous studies show-
ing that cardiac remodeling in mice with global (not car-
diomyocyte speciﬁc) GC-A disruption is markedly
inhibited by genetic or pharmacological blockade of the
AT1 receptor [27]. As a corollary, Ang II-induced cardiac
remodeling was suppressed in mice overexpressing brain
natriuretic peptide (BNP) in the circulation, a member of
the natriuretic peptide family which also activates the
GC-A receptor, although with less afﬁnity than ANP [43].
However, these studies could not distinguish between
systemic and cardiac interactions of ANP/BNP and Ang II.
Our study adds an important piece of information, because
the conditional, cardiomyocyte-restricted disruption of the
GC-A gene in mice allowed us to speciﬁcally dissect
the local cardiac from the systemic interactions between
the ANP/GC-A and Ang II/AT1 systems. Furthermore, it
characterizes PKG I and RGS2 as molecular effectors
mediating the cross-talk between these pathways in cardiac
remodeling.
Our observation of a differential regulation of Ang
II- but not b-adrenergic stimulation of myocyte calcium
handling by ANP is in agreement with a study by Takimoto
et al. [44] which also observed that b-adrenergic calcium
and contractile responses of adult myocytes and intact
hearts are unaffected by ANP/GC-A-elicited cGMP pro-
duction at the plasma membrane. In contrast, nitric oxide
(NO)-stimulated cGMP production in the cytosol (which is
mediated by the soluble guanylyl cyclase, sGC), markedly
blunted the cardiac contractile responses to ISO [44, 50].
Extending these observations, cardiac overexpression of
endothelial NO synthase in transgenic mice attenuated
cardiac hypertrophy induced by chronic ISO infusion [36].
Hence, these studies indicate that the NO/sGC/cGMP
system acts as a negative modulator of both the cardiac
contractile and hypertrophic responses to b-adrenergic
stimulation [36, 44]. In contrast, the ANP/GC-A/cGMP
system does not regulate these responses (present study and
[44]). In conclusion, our observations support the notion
that cGMP synthesized by sGC (in response to NO) and
membrane-bound GC-A (in response to ANP) does not
feed a common cGMP pool in cardiac myocytes, but
instead remains spatially and functionally compartmental-
ized to modulate different targets and thereby different
myocyte functions.
Counteraction of the cardiac Ang II effects
by ANP/GC-A/cGMP involves PKG I and RGS2
At least two cGMP-stimulated proteins (as third messen-
gers) are expressed in myocytes: PKG I; and phosphodi-
esterase (PDE) 2, a dual substrate esterase, which appears
to hydrolyze cGMP under resting conditions [2], but targets
cAMP in the presence of b-adrenergic stimulation [33]. In
cultured endothelial cells, the ANP/GC-A/cGMP-signal-
ling pathway stimulates PDE2 activity, decreases intra-
cellular cAMP concentrations and thereby increases
endothelial barrier functions [42]. However, in cardio-
myocytes, the lack of effects of ANP on the calcium and
inotropic responses to ISO (see present study and [44])
suggests that PDE 2 activity is not modulated by the pool
of cGMP formed after ANP/GC-A stimulation. This could
be due to spatial compartmentalization or could be related
to different concentrations of cGMP reached after GC-A
stimulation in myocytes (expressing low levels of GC-A)
when compared with endothelia (with very dense GC-A
expression) [25, 26].
Instead, using both a genetic and a pharmacological
approach, our study demonstrates that PKG I is a down-
stream target activated by the ANP/GC-A/cGMP system in
cardiomyocytes. As illustrated, the counter regulation of
the Ca
2? responses of isolated adult myocytes to Ang II by
ANP was absent in PKG I-deﬁcient myocytes and also in
wild-type myocytes pre-treated with the selective PKG I
inhibitor, Rp-8-Br-PET-cGMP. However, the in vivo rel-
evance of these in vitro ﬁndings has still to be demon-
strated. Mice with a global deletion of PKG I show severe
gastrointestinal dysfunction and high mortality before
6 weeks of age [38]. To circumvent these limitations,
smooth muscle rescue mice were generated, in which PKG
I expression is restored selectively in smooth muscle, but
not in other cell types of PKG I null mice [49]. We used
these rescue mice not only to isolate adult myocytes for our
ex vivo calcium studies, but also to study the impact of
PKG I deletion on the cardiac hypertrophic responses to
chronic Ang II treatment. Ang II was administered for
14 days to eight 20-week-old male PKG I rescue mice and
eight litter-matched control mice (300 ng Ang II/kg BW/
min with osmotic minipumps). Interestingly, the cardiac
hypertrophic responses to Ang II were attenuated in the
PKG I mutants when compared with control mice (data
not shown). However, it is important to note that this group
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123of rescue mice also showed a systemic phenotype. Unfor-
tunately, these animals had anemia and splenomegalia [7].
In addition, and in contrast to the normal blood pressure of
10-week-old PKG I rescue mice [49], we observed in the
‘‘older’’ rescue mice pronounced arterial hypotension
(decreases in SBP by *20 mmHg measured by the tail
cuff method, both before and during Ang II administration,
data not shown). Thus, it is likely that the attenuated
hypertrophic response of the PKG I mutants to Ang II is
related to their systemic phenotype, especially to arterial
hypotension. Hence, although our own and published data
support an important protective role for myocardial PKG I
in pathological cardiac hypertrophy in vivo [45], a ﬁnal
proof is lacking.
At least in vitro several proteins centrally involved in
myocyte calcium handling have been shown to be regu-
lated by PKG I, such as the L-type Ca
2? channel (inhi-
bition), phospholemman (inhibition) and phospholamban
(inhibition, resulting in enhanced SR calcium uptake by
SERCA) [6]. Our observation that the ANP/GC-A/cGMP/
PKG I pathway selectively inhibits the myocyte Ca
2?-
responses to Ang II, but not to ISO, suggested a selective
modulation of Gaq/11-coupled receptor signalling. The
regulator of G protein signalling (RGS)-2 is a selective
and negative regulator of Gq/11 proteins in the cardiovas-
cular system which is activated by PKG I [51]. For
instance, in vascular smooth muscle cells the nitric oxide/
sGC/cGMP/PKG I pathway regulates the degradation of
RGS2 and promotes its association with the plasma
membrane by a mechanism requiring its PKG I phos-
phorylation sites [35]. By regulating RGS2 plasma mem-
brane association and degradation, PKG I therefore may
control its inhibitory effect on Gq/11-coupled receptors
[35]. RGS2-deﬁcient mice (RGS2
-/-) are hypertensive,
exhibit increased vasoconstrictory responses to vasopres-
sin and other hormones activating Gq/11-coupled receptors
and diminished vasodilating responses to nitric oxide/
cGMP/PKG I signalling [14, 15, 35, 46]. Consistent with
these observations, we found in the present study that the
calcium responses of RGS2
-/- myocytes to Ang II were
enhanced, whereas responses to b-adrenergic stimulation
were unaltered. Notably, the inhibitory effect of ANP on
calcium responses to Ang II was absent in RGS2
-/-
myocytes. Concomitantly, in transfected HEK293 cells
ANP, via GC-A/PKG I signalling, dramatically enhanced
RGS2 expression and membrane localization. We con-
clude from these experiments that ANP, via GC-A/cGMP/
PKG I, enhances the expression and/or phosphorylation of
RGS2 and thereby counteracts AngII/AT1 signalling. In
turn, inhibition of ANP/GC-A signalling (in CM GC-A
KO mice) enhances the cardiac hypertrophic responses to
Ang II. Unfortunately for technical reasons, we could not
complement these experiments with analyses of RGS2
expression and/or phosphorylation in wild type when
compared with GC-A- or PKG I-deﬁcient myocytes. There
are no phospho-speciﬁc antibodies available. Worse,
Western-blot analyses revealed that commercially avail-
able anti-RGS2 antibodies unspeciﬁcally recognize an
immunoreactive protein of 28 kDa (the MW of RGS2) in
tissues from both wild-type and RGS2-deﬁcient mice (not
shown). Hence, in our hands commercially available
antibodies were unsuitable to study RGS2 expression in
native tissues.
Collectively, our ﬁndings are compatible with the notion
that PKG I is the downstream target activated by the ANP/
GC-A/cGMP-signalling pathway in cardiac myocytes.
cGMP/PKG I-mediated modulation of RGS2 and sub-
sequent inhibition of AT1/Gq-signalling appear to mediate
the speciﬁc counter regulation of the calcium responses of
myocytes to Ang II by ANP.
TRPC3/C6 channels are involved in the calcium
responses of adult myocytes to Ang II
Studies in neonatal rat cardiomyocytes have indicated that
Ang II induces TRPC3/C6 activation through Gaq-phos-
pholipase C (PLC) signalling pathways [34]. DAG, gen-
erated by PLC activation, directly activates TRPC3/C6
[17]. In neonatal myocytes, this causes slow depolariza-
tion of the membrane potential and concomitantly
increases the frequency of spontaneous ﬁring due to
activation of L-type Ca
2? channel [34]. Indeed, in our
study with adult murine ventricular myocytes, the effects
of Ang II both on Ca
2? transients and on L-type Ca
2?
currents were abolished in TRPC3/C6-deﬁcient myocytes.
In addition, BTP2, which inhibits the activity of TRPC
channels [13], abolished the calcium responses to Ang II.
Taken together these experiments demonstrate that TRPC
channels are indispensable for the calcium responses of
adult ventricular myocytes to Ang II. In contrast,
b-adrenergic stimulation of Ca
2? currents and Ca
2?
i
handling was not altered by genetic or pharmacological
blockade of TRPC channels. However, intriguingly, in
whole-cell current-clamp recordings, we did not observe
differences in the resting membrane potential of wild-type
and TRPC3/C6-deﬁcient myocytes or changes of the
membrane potential in response to Ang II (data not
shown). These unexpected ﬁndings point towards a novel
mechanism of TRPC3/C6 activity regulating L-type Ca
2?
channel (LTCC) activity in response to Ang II which we
will try to elucidate in our future studies. One hypothesis
is that TRPC-mediated Ca
2? entry activates CaMKII,
which has been shown to be associated with cardiac
LTCC complexes and increases channel open probability
to dynamically increase Ca
2? current by a process called
facilitation [10].
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123Conclusion
Patients with cardiac hypertrophy and/or congestive heart
failure have elevated plasma levels of ANP and BNP [25,
26]. However, the cardiovascular and cGMP responses to
these hormones are markedly attenuated, indicating
impaired receptor or post-receptor responsiveness of GC-A
[25, 26]. Concurrently, the deleterious role of the local
renin–angiotensin–aldosterone system in cardiac remodel-
ing has been demonstrated by many experimental and
clinical reports. Our study emphasizes that a disturbance of
the delicate systemic and also local, cardiac balance
between the ANP and RAA systems can critically con-
tribute to the progression of cardiac hypertrophy.
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